Skip to main content

Piper Sandler Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Thu May 1, 2025

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $7.60.

Protect Your Portfolio Against Market Uncertainty

Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and Corcept Therapeutics. According to TipRanks, Amsellem has an average return of -1.6% and a 41.88% success rate on recommended stocks.

Currently, the analyst consensus on SAGE Therapeutics is a Hold with an average price target of $8.42.

See today’s best-performing stocks on TipRanks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.82 million and a GAAP net loss of $95.78 million. In comparison, last year the company earned a revenue of $77.97 million and had a GAAP net loss of $32.71 million

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).